Engineered T-Cell Therapies for Cancer
Fully diluted ownership
Value of Syncona holding
£88.6m (as at 26 September 2017)
Autolus is a private biopharmaceutical company focused on the development and commercialisation of engineered T-cell immunotherapy products for haematological and solid tumours, based on its proprietary T-cell programming technology.
The Autolus approach uses a patient’s own immune cells (T-cells) to target and destroy cancerous cells and provide long-term protection from disease. The T-cells are collected from the patient’s blood, re-engineered outside the body, and returned to the patient where they mount an immune response and kill tumour cells.
Blood cancers, including lymphomas, leukaemias and multiple myeloma, represent 10% of all cancer diagnoses, with around 58,000 deaths in the US in 2016.
- Martin Murphy
- Edward Hodgkin
CSO & Founder
- Martin Pule